Institutional members access full text with Ovid®

Share this article on:

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs

Falissard, Brunoa; Mauri, Maurod; Shaw, Kene; Wetterling, Tilmanf; Doble, Adamc; Giudicelli, Agnèsb; De Hert, Marcg

International Clinical Psychopharmacology: November 2011 - Volume 26 - Issue 6 - p 291–302
doi: 10.1097/YIC.0b013e32834a5bf6
Original Articles

The objective of this crosssectional study was to estimate the prevalence of metabolic disorders and hypertension in patients with schizophrenia and to compare prevalence between patients treated with first-generation (FGA) and second-generation (SGA) antipsychotic drugs. The study included 2270 adults with schizophrenia. Patients were assigned to an FGA or SGA stratum on the basis of current treatment. Data were collected on sociodemographic, lifestyle and clinical variables. Blood pressure, waist and hip circumference, blood glucose, triglycerides and cholesterol were measured. The primary evaluation criterion was the prevalence of a glycaemic disorder. Secondary criteria were the prevalence of dyslipidaemia, obesity, hypertension and metabolic syndrome. A propensity score was used to control imbalance between strata. The prevalence of glycaemic disorders was 31.1% (FGA) and 27.6% (SGA). No between-strata difference in prevalence was observed for glycaemic disorders, dyslipidaemia or metabolic syndrome. The prevalence of hypertension was higher (P=0.033) in the FGA group. The proportion of women (but not men) who were overweight or obese was higher in the SGA group (P=0.035), as was the proportion reporting weight gain of more than 5 kg (P<0.001). In an exploratory unadjusted post-hoc analysis, significantly higher frequencies of dysglycaemia (28.5 vs. 22.0%; P=0.006), low HDL cholesterol (35.3 vs. 29.7%; P=0.023) and metabolic syndrome (36.7 vs. 30.7%; P=0.021) were observed in patients taking SGAs considered to carry high metabolic risk compared with those taking low-risk agents. In conclusion, metabolic disorders are prevalent in patients with schizophrenia treated with antipsychotics and are under-diagnosed and under-treated.

aINSERM U669, Université Paris-Sud and Université Paris-Descartes

bSanofi-aventis, Paris

cFoxymed, Fresnes, France

dClinica Psichiatrica, DPFNB, Università di Pisa, Pisa, Italy

eQueen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Cosham, UK

fVivantes Klinikum Hellersdorf, Klinik für Psychiatrie und Psychotherapie – Gerontopsychiatrie, Berlin, Germany

gUPC KUL Campus Kortenberg, Kortenberg, Belgium

Correspondence to Professor Bruno Falissard, INSERM U669, PSIGIAM, ‘Paris Sud Innovation Group in Adolescent Mental Health’, Maison de Solenn, 97 Boulevard de Port Royal, Paris cedex 14 75679, France Tel: +33 6 81 82 70 76; fax: +33 1 58 41 28 43; e-mail:

Received July 14, 2010

Accepted June 28, 2011

© 2011 Lippincott Williams & Wilkins, Inc.